BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-97. [PMID: 22820290 DOI: 10.1172/JCI63455] [Cited by in Crossref: 562] [Cited by in F6Publishing: 348] [Article Influence: 56.2] [Reference Citation Analysis]
Number Citing Articles
1 López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med (Lausanne) 2020;7:527059. [PMID: 33102495 DOI: 10.3389/fmed.2020.527059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Włodarski A, Strycharz J, Wróblewski A, Kasznicki J, Drzewoski J, Śliwińska A. The Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress. Int J Mol Sci 2020;21:E6902. [PMID: 32962281 DOI: 10.3390/ijms21186902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Liang WC, Wang Y, Xiao LJ, Wang YB, Fu WM, Wang WM, Jiang HQ, Qi W, Wan DC, Zhang JF. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol. 2014;11:845-854. [PMID: 24921656 DOI: 10.4161/rna.29356] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
4 Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287-314. [PMID: 24079833 DOI: 10.1146/annurev-pathol-012513-104715] [Cited by in Crossref: 929] [Cited by in F6Publishing: 952] [Article Influence: 103.2] [Reference Citation Analysis]
5 Gambari R, Brognara E, Spandidos DA, Fabbri E. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol 2016;49:5-32. [PMID: 27175518 DOI: 10.3892/ijo.2016.3503] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 18.0] [Reference Citation Analysis]
6 Katsura A, Morishita A, Iwama H, Tani J, Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, Nomura T, Miyoshi H, Yoneyama H, Himoto T, Fujiwara S, Kobara H, Mori H, Niki T, Ono M, Hirashima M, Masaki T. MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis. Int J Mol Med 2015;35:877-84. [PMID: 25672270 DOI: 10.3892/ijmm.2015.2092] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
7 Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014;49:589-593. [PMID: 24531873 DOI: 10.1007/s00535-014-0932-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
8 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol 2018; 10(9): 558-570 [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
9 Udoh US, Valcin JA, Gamble KL, Bailey SM. The Molecular Circadian Clock and Alcohol-Induced Liver Injury. Biomolecules 2015;5:2504-37. [PMID: 26473939 DOI: 10.3390/biom5042504] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
10 Shukla L, Yuan Y, Shayan R, Greening DW, Karnezis T. Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration. Front Pharmacol. 2020;11:158. [PMID: 32194404 DOI: 10.3389/fphar.2020.00158] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
11 Tsai HC, Tsou HH, Lin CC, Chen SC, Cheng HW, Liu TY, Chen WS, Jiang JK, Yang SH, Chang SC, Teng HW, Wang HT. Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway. Sci Rep 2021;11:12590. [PMID: 34131238 DOI: 10.1038/s41598-021-92035-z] [Reference Citation Analysis]
12 Lu Y, Gao W, Zhang C, Wen S, Huangfu H, Kang J, Wang B. Hsa-miR-301a-3p Acts as an Oncogene in Laryngeal Squamous Cell Carcinoma via Target Regulation of Smad4. J Cancer 2015;6:1260-75. [PMID: 26640587 DOI: 10.7150/jca.12659] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
13 de Paula Simino LA, de Fante T, Figueiredo Fontana M, Oliveira Borges F, Torsoni MA, Milanski M, Velloso LA, Souza Torsoni A. Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet. Nutr Metab (Lond) 2017;14:16. [PMID: 28239403 DOI: 10.1186/s12986-017-0168-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
14 Della Peruta M, Badar A, Rosales C, Chokshi S, Kia A, Nathwani D, Galante E, Yan R, Arstad E, Davidoff AM. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Hum Gene Ther. 2015;26:94-103. [PMID: 25569358 DOI: 10.1089/hum.2014.052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
15 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
16 Liu J, Ning C, Li B, Li R, Wu W, Liu H. Hepatic microRNAome reveals potential microRNA-mRNA pairs association with lipid metabolism in pigs. Asian-Australas J Anim Sci 2019;32:1458-68. [PMID: 30208692 DOI: 10.5713/ajas.18.0438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med 2016;5:E30. [PMID: 26950158 DOI: 10.3390/jcm5030030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
18 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49. [PMID: 23836234 DOI: 10.1038/nm.3248] [Cited by in Crossref: 394] [Cited by in F6Publishing: 364] [Article Influence: 43.8] [Reference Citation Analysis]
19 Wang G, Cheng Y, Liu Y. Comprehensive Evaluation of a Donated After Circulatory Death (DCD) Donor Liver Model in Minipigs. Ann Transplant 2018;23:758-66. [DOI: 10.12659/aot.911072] [Reference Citation Analysis]
20 Norata GD, Sala F, Catapano AL, Fernández-Hernando C. MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Atherosclerosis 2013;227:209-15. [PMID: 23260873 DOI: 10.1016/j.atherosclerosis.2012.11.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
21 Menon B, Gulappa T, Menon KM. miR-122 Regulates LH Receptor Expression by Activating Sterol Response Element Binding Protein in Rat Ovaries. Endocrinology 2015;156:3370-80. [PMID: 26125464 DOI: 10.1210/en.2015-1121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
22 Mahmoudian-Sani MR, Asgharzade S, Alghasi A, Saeedi-Boroujeni A, Adnani Sadati SJ, Moradi MT. MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol 2019;10:789-96. [PMID: 31392060 DOI: 10.21037/jgo.2019.02.14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
23 Kurtz CL, Fannin EE, Toth CL, Pearson DS, Vickers KC, Sethupathy P. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep 2015;5:12911. [PMID: 26246194 DOI: 10.1038/srep12911] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
24 Dong J, Liang YZ, Zhang J, Wu LJ, Wang S, Hua Q, Yan YX. Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease. J Atheroscler Thromb 2017;24:430-41. [PMID: 27629254 DOI: 10.5551/jat.35923] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
25 Gerlach CV, Vaidya VS. MicroRNAs in injury and repair. Arch Toxicol 2017;91:2781-97. [PMID: 28501916 DOI: 10.1007/s00204-017-1974-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
26 Lu XF, Zhou YJ, Zhang L, Ji HJ, Li L, Shi YJ, Bu H. Loss of Dicer1 impairs hepatocyte survival and leads to chronic inflammation and progenitor cell activation. World J Gastroenterol 2015; 21(21): 6591-6603 [PMID: 26074697 DOI: 10.3748/wjg.v21.i21.6591] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
27 Baffy G. MicroRNAs in Nonalcoholic Fatty Liver Disease. J Clin Med. 2015;4:1977-1988. [PMID: 26690233 DOI: 10.3390/jcm4121953] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
28 Ohde D, Brenmoehl J, Walz C, Tuchscherer A, Wirthgen E, Hoeflich A. Comparative analysis of hepatic miRNA levels in male marathon mice reveals a link between obesity and endurance exercise capacities. J Comp Physiol B 2016;186:1067-78. [PMID: 27278158 DOI: 10.1007/s00360-016-1006-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ishida M, Selaru FM. miRNA-Based Therapeutic Strategies. Curr Anesthesiol Rep 2013;1:63-70. [PMID: 23524956 DOI: 10.1007/s40139-012-0004-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
30 Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, Wu W, Brojigin N, Kaneoka Y, Maeda A. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer. 2013;13:99. [PMID: 23496901 DOI: 10.1186/1471-2407-13-99] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
31 Wang N, Wang Q, Shen D, Sun X, Cao X, Wu D. Downregulation of microRNA-122 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by activating epithelial-mesenchymal transition. Onco Targets Ther. 2016;9:2035-2047. [PMID: 27103830 DOI: 10.2147/ott.s92378] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
32 Matsuda A, Yan IK, Foye C, Parasramka M, Patel T. MicroRNAs as paracrine signaling mediators in cancers and metabolic diseases. Best Pract Res Clin Endocrinol Metab 2016;30:577-90. [PMID: 27923452 DOI: 10.1016/j.beem.2016.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Shibata C, Otsuka M, Kishikawa T, Ohno M, Yoshikawa T, Takata A, Koike K. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol 2015; 7(1): 1-6 [PMID: 25624991 DOI: 10.4254/wjh.v7.i1.1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
34 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
35 Matsuzaki J, Ochiya T. Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review. J Clin Biochem Nutr 2018;63:6-11. [PMID: 30087537 DOI: 10.3164/jcbn.17-123] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
36 Das A, Basu S, Bandyopadhyay D, Mukherjee K, Datta D, Chakraborty S, Jana S, Adak M, Bose S, Chakrabarti S, Swarnakar S, Chakrabarti P, Bhattacharyya SN. Inhibition of extracellular vesicle-associated MMP2 abrogates intercellular hepatic miR-122 transfer to liver macrophages and curtails inflammation. iScience 2021;24:103428. [PMID: 34877493 DOI: 10.1016/j.isci.2021.103428] [Reference Citation Analysis]
37 Ben-Moshe S, Shapira Y, Moor AE, Manco R, Veg T, Bahar Halpern K, Itzkovitz S. Spatial sorting enables comprehensive characterization of liver zonation. Nat Metab 2019;1:899-911. [PMID: 31535084 DOI: 10.1038/s42255-019-0109-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
38 Kalla R, Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH, Satsangi J. MicroRNAs: new players in IBD. Gut 2015;64:504-17. [PMID: 25475103 DOI: 10.1136/gutjnl-2014-307891] [Cited by in Crossref: 144] [Cited by in F6Publishing: 139] [Article Influence: 18.0] [Reference Citation Analysis]
39 Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell 2019;179:1033-55. [PMID: 31730848 DOI: 10.1016/j.cell.2019.10.017] [Cited by in Crossref: 264] [Cited by in F6Publishing: 257] [Article Influence: 132.0] [Reference Citation Analysis]
40 Wang Y, Liang H, Jin F, Yan X, Xu G, Hu H, Liang G, Zhan S, Hu X, Zhao Q, Liu Y, Jiang ZY, Zhang CY, Chen X, Zen K. Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway. Proc Natl Acad Sci U S A 2019;116:6162-71. [PMID: 30867286 DOI: 10.1073/pnas.1814139116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
41 Zhang YC, Xu Z, Zhang TF, Wang YL. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol 2015; 21(34): 9853-9862 [PMID: 26379392 DOI: 10.3748/wjg.v21.i34.9853] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
42 He X, Li J, Guo W, Liu W, Yu J, Song W, Dong L, Wang F, Yu S, Zheng Y, Chen S, Kong Y, Liu C. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget 2015;6:2302-14. [PMID: 25544773 DOI: 10.18632/oncotarget.2955] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
43 Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46-57. [PMID: 25190143 DOI: 10.1038/cdd.2014.136] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 10.6] [Reference Citation Analysis]
44 Aranda JF, Madrigal-Matute J, Rotllan N, Fernández-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med. 2013;64:31-39. [PMID: 23871755 DOI: 10.1016/j.freeradbiomed.2013.07.014] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
45 Li C, Lu L, Qi Z, Zhu Y, Su F, Zhao P, Dong H. Transcriptome and miRNome Analysis Provide New Insight Into Host Lipid Accumulation, Innate Immunity, and Viral Persistence in Hepatitis C Virus Infection in vitro. Front Microbiol 2020;11:535673. [PMID: 33101221 DOI: 10.3389/fmicb.2020.535673] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Shyu YC, Lee TL, Lu MJ, Chen JR, Chien RN, Chen HY, Lin JF, Tsou AP, Chen YH, Hsieh CW, Huang TS. miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J Transl Med 2016;14:200. [PMID: 27370270 DOI: 10.1186/s12967-016-0956-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
47 Ali N, Allam H, Bader T, May R, Basalingappa KM, Berry WL, Chandrakesan P, Qu D, Weygant N, Bronze MS. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One. 2013;8:e80304. [PMID: 24260365 DOI: 10.1371/journal.pone.0080304] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
48 Gallo A, Miceli V, Bulati M, Iannolo G, Contino F, Conaldi PG. Viral miRNAs as Active Players and Participants in Tumorigenesis. Cancers (Basel) 2020;12:E358. [PMID: 32033193 DOI: 10.3390/cancers12020358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
49 Ferreira DM, Afonso MB, Rodrigues PM, Simão AL, Pereira DM, Borralho PM, Rodrigues CM, Castro RE. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol 2014;34:1100-20. [PMID: 24421392 DOI: 10.1128/MCB.00420-13] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
50 Gramantieri L, Giovannini C, Piscaglia F, Fornari F. MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:369-85. [PMID: 34012928 DOI: 10.2147/JHC.S268292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Rotllan N, Price N, Pati P, Goedeke L, Fernández-Hernando C. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 2016;246:352-60. [PMID: 26828754 DOI: 10.1016/j.atherosclerosis.2016.01.025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
52 Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramírez CM, Goedeke L, Rotllan N, Bonora E, Hughes AD, Santer P, Fernández-Hernando C, Tilg H, Willeit J, Kiechl S, Mayr M. Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. Diabetes 2017;66:347-57. [PMID: 27899485 DOI: 10.2337/db16-0731] [Cited by in Crossref: 112] [Cited by in F6Publishing: 109] [Article Influence: 18.7] [Reference Citation Analysis]
53 Gu P, Liu FG, Sun XG, Chen L, Li L, Liu XS. Effect of formaldehyde on miRNA122 and its downstream molecules a disintegrin and metalloproteinase 10 and serum response factor in the liver of mice. Shijie Huaren Xiaohua Zazhi 2015; 23(34): 5435-5442 [DOI: 10.11569/wcjd.v23.i34.5435] [Reference Citation Analysis]
54 Shi L, Zheng X, Fan Y, Yang X, Li A, Qian J. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells. BMC Gastroenterol 2019;19:130. [PMID: 31340754 DOI: 10.1186/s12876-019-1048-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
55 Zhou L, Hussain MM. Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis. Arterioscler Thromb Vasc Biol 2017;37:786-93. [PMID: 28336556 DOI: 10.1161/ATVBAHA.117.309247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
56 Prashad N. miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth. Oncotarget 2018;9:33186-201. [PMID: 30237861 DOI: 10.18632/oncotarget.26046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
57 Lian JY, Tuo BG. Role of non-coding RNAs in development and progression of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(3): 396-403 [DOI: 10.11569/wcjd.v23.i3.396] [Reference Citation Analysis]
58 Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475-488. [PMID: 23800994 DOI: 10.1038/nrm3611] [Cited by in Crossref: 793] [Cited by in F6Publishing: 730] [Article Influence: 88.1] [Reference Citation Analysis]
59 Lee CH, Lee YJ, Kim JH, Lim JH, Kim JH, Han W, Lee SH, Noh GJ, Lee SW. Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase. J Virol. 2013;87:7064-7074. [PMID: 23596299 DOI: 10.1128/jvi.00405-13] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
60 Momen-Heravi F, Catalano D, Talis A, Szabo G, Bala S. Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice. Mol Ther Nucleic Acids 2021;25:155-67. [PMID: 34458001 DOI: 10.1016/j.omtn.2021.05.007] [Reference Citation Analysis]
61 Vickers KC, Rye KA, Tabet F. MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond). 2014;126:183-194. [PMID: 24102098 DOI: 10.1042/cs20130203] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
62 Xiao Z, Shen J, Zhang L, Li M, Hu W, Cho C. Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects. Oncol Lett. 2018;15:3395-3402. [PMID: 29467864 DOI: 10.3892/ol.2018.7758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
63 Vincent R, Sanyal A. Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. Curr Pathobiol Rep 2014;2:109-15. [PMID: 25574453 DOI: 10.1007/s40139-014-0049-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
64 Smolle E, Haybaeck J. Non-coding RNAs and lipid metabolism. Int J Mol Sci 2014;15:13494-513. [PMID: 25093715 DOI: 10.3390/ijms150813494] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
65 Dhungel B, Ramlogan-Steel CA, Layton CJ, Steel JC. miRNA122a regulation of gene therapy vectors targeting hepatocellular cancer stem cells. Oncotarget 2018;9:23577-88. [PMID: 29805757 DOI: 10.18632/oncotarget.25280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
66 George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35:63-74. [PMID: 25632936 DOI: 10.1055/s-0034-1397350] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
67 Yu F, Jiang Z, Chen B, Dong P, Zheng J. NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. J Mol Med (Berl) 2017;95:1191-202. [PMID: 28864835 DOI: 10.1007/s00109-017-1586-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
68 Coffey S, Williams MJ, Phillips LV, Galvin IF, Bunton RW, Jones GT. Integrated microRNA and messenger RNA analysis in aortic stenosis. Sci Rep 2016;6:36904. [PMID: 27876829 DOI: 10.1038/srep36904] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
69 Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, Wang Z, Qi C, Wang T, Wang X. Maternal chromium restriction modulates miRNA profiles related to lipid metabolism disorder in mice offspring. Exp Biol Med (Maywood) 2017;242:1444-52. [PMID: 28669221 DOI: 10.1177/1535370217719059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
71 Vallabhajosyula P, Korutla L, Habertheuer A, Yu M, Rostami S, Yuan CX, Reddy S, Liu C, Korutla V, Koeberlein B, Trofe-Clark J, Rickels MR, Naji A. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest. 2017;127:1375-1391. [PMID: 28319051 DOI: 10.1172/jci87993] [Cited by in Crossref: 75] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
72 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-496. [PMID: 23748342 DOI: 10.1038/nrmicro3046] [Cited by in Crossref: 262] [Cited by in F6Publishing: 239] [Article Influence: 29.1] [Reference Citation Analysis]
73 Beltrán-Anaya FO, Cedro-Tanda A, Hidalgo-Miranda A, Romero-Cordoba SL. Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism. Front Physiol 2016;7:342. [PMID: 27551267 DOI: 10.3389/fphys.2016.00342] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
74 Li Y, Yamane D, Masaki T, Lemon SM. The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Nat Rev Microbiol 2015;13:544-58. [PMID: 26256788 DOI: 10.1038/nrmicro3506] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
75 Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535-548. [PMID: 23817310 DOI: 10.1038/nrg3471] [Cited by in Crossref: 230] [Cited by in F6Publishing: 214] [Article Influence: 25.6] [Reference Citation Analysis]
76 Elchaninov A, Lokhonina A, Nikitina M, Vishnyakova P, Makarov A, Arutyunyan I, Poltavets A, Kananykhina E, Kovalchuk S, Karpulevich E, Bolshakova G, Sukhikh G, Fatkhudinov T. Comparative Analysis of the Transcriptome, Proteome, and miRNA Profile of Kupffer Cells and Monocytes. Biomedicines 2020;8:E627. [PMID: 33352881 DOI: 10.3390/biomedicines8120627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
77 Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15:137-151. [PMID: 29317776 DOI: 10.1038/nrgastro.2017.169] [Cited by in Crossref: 157] [Cited by in F6Publishing: 174] [Article Influence: 39.3] [Reference Citation Analysis]
78 Liu MX, Gao M, Li CZ, Yu CZ, Yan H, Peng C, Li Y, Li CG, Ma ZL, Zhao Y. Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis. Acta Pharmacol Sin. 2017;38:660-671. [PMID: 28112179 DOI: 10.1038/aps.2016.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
79 Wang M, Yu F, Li P. Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E258. [PMID: 30072625 DOI: 10.3390/cancers10080258] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 13.5] [Reference Citation Analysis]
80 Xie J, Burt DR, Gao G. Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis. 2015;35:81-88. [PMID: 25632938 DOI: 10.1055/s-0034-1397352] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
81 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
82 Hsu SH, Delgado ER, Otero PA, Teng KY, Kutay H, Meehan KM, Moroney JB, Monga JK, Hand NJ, Friedman JR, Ghoshal K, Duncan AW. MicroRNA-122 regulates polyploidization in the murine liver. Hepatology 2016;64:599-615. [PMID: 27016325 DOI: 10.1002/hep.28573] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
83 Jin K, Li T, Sánchez-Duffhues G, Zhou F, Zhang L. Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget 2017;8:22145-65. [PMID: 27888618 DOI: 10.18632/oncotarget.13530] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
84 Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, Roderburg C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. Int J Mol Sci. 2018;19:pii: E261. [PMID: 29337905 DOI: 10.3390/ijms19010261] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
85 Tomasetti M, Lee W, Santarelli L, Neuzil J. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med 2017;49:e285. [PMID: 28104913 DOI: 10.1038/emm.2016.153] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 20.0] [Reference Citation Analysis]
86 Lin J, Maimaitiyiming A, Chen S, Xiao M, Xian Z. Hypoxia-induced miR-27 and miR-195 regulate ATP consumption, viability, and metabolism of rat cardiomyocytes by targeting PPARγ and FASN expression. Aging (Albany NY) 2021;13:10158-74. [PMID: 33819184 DOI: 10.18632/aging.202778] [Reference Citation Analysis]
87 Zhang X, Price NL, Fernández-Hernando C. Non-coding RNAs in lipid metabolism. Vascul Pharmacol 2019;114:93-102. [PMID: 29929012 DOI: 10.1016/j.vph.2018.06.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
88 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
89 Kostyniuk DJ, Culbert BM, Mennigen JA, Gilmour KM. Social status affects lipid metabolism in rainbow trout, Oncorhynchus mykiss. Am J Physiol Regul Integr Comp Physiol 2018;315:R241-55. [PMID: 29561648 DOI: 10.1152/ajpregu.00402.2017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
90 Piccinin E, Arconzo M, Graziano G, Vacca M, Peres C, Bellafante E, Villani G, Moschetta A. Hepatic microRNA Expression by PGC-1α and PGC-1β in the Mouse. Int J Mol Sci 2019;20:E5735. [PMID: 31731670 DOI: 10.3390/ijms20225735] [Reference Citation Analysis]
91 Jin HY, Xiao C. MicroRNA Mechanisms of Action: What have We Learned from Mice? Front Genet 2015;6:328. [PMID: 26635864 DOI: 10.3389/fgene.2015.00328] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
92 Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal K. Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure. Am J Pathol 2013;183:1719-30. [PMID: 24113455 DOI: 10.1016/j.ajpath.2013.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
93 Wu HQ, Cheng ML, Lai JM, Wu HH, Chen MC, Liu WH, Wu WH, Chang PM, Huang CF, Tsou AP, Shiao MS, Wang FS. Flux balance analysis predicts Warburg-like effects of mouse hepatocyte deficient in miR-122a. PLoS Comput Biol 2017;13:e1005618. [PMID: 28686599 DOI: 10.1371/journal.pcbi.1005618] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
94 Szabo G, Csak T. Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci. 2016;61:1314-1324. [PMID: 26769057 DOI: 10.1007/s10620-015-4002-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
95 Ragusa M, Statello L, Maugeri M, Barbagallo C, Passanisi R, Alhamdani MS, Li Destri G, Cappellani A, Barbagallo D, Scalia M, Valadi H, Hoheisel JD, Di Pietro C, Purrello M. Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications. Oncoscience 2014;1:132-57. [PMID: 25594007 DOI: 10.18632/oncoscience.19] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
96 Xu H, Xu SJ, Xie SJ, Zhang Y, Yang JH, Zhang WQ, Zheng MN, Zhou H, Qu LH. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway. Elife 2019;8:e41159. [PMID: 30735121 DOI: 10.7554/eLife.41159] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
97 Chien CH, Chiang-Hsieh YF, Tsou AP, Weng SL, Chang WC, Huang HD. Large-scale investigation of human TF-miRNA relations based on coexpression profiles. Biomed Res Int 2014;2014:623078. [PMID: 24995316 DOI: 10.1155/2014/623078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
98 Azevedo-Pouly AC, Sutaria DS, Jiang J, Elgamal OA, Amari F, Allard D, Grippo PJ, Coppola V, Schmittgen TD. miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal. Funct Integr Genomics 2017;17:203-12. [PMID: 27541609 DOI: 10.1007/s10142-016-0512-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
99 Starlinger P, Hackl H, Pereyra D, Skalicky S, Geiger E, Finsterbusch M, Tamandl D, Brostjan C, Grünberger T, Hackl M, Assinger A. Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures. Hepatology 2019;69:2636-51. [PMID: 30779441 DOI: 10.1002/hep.30572] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
100 Hsu SH, Ghoshal K. MicroRNAs in Liver Health and Disease. Curr Pathobiol Rep 2013;1:53-62. [PMID: 23565350 DOI: 10.1007/s40139-012-0005-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
101 Olive V, Minella AC, He L. Outside the coding genome, mammalian microRNAs confer structural and functional complexity. Sci Signal 2015;8:re2. [PMID: 25783159 DOI: 10.1126/scisignal.2005813] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
102 Takahashi A, Suzuki T, Soeda S, Takaoka S, Kobori S, Yamaguchi T, Mohamed HMA, Yanagiya A, Abe T, Shigeta M, Furuta Y, Kuba K, Yamamoto T. The CCR4-NOT complex maintains liver homeostasis through mRNA deadenylation. Life Sci Alliance 2020;3:e201900494. [PMID: 32238456 DOI: 10.26508/lsa.201900494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Valdmanis PN, Gu S, Chu K, Jin L, Zhang F, Munding EM, Zhang Y, Huang Y, Kutay H, Ghoshal K, Lisowski L, Kay MA. RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nat Med 2016;22:557-62. [PMID: 27064447 DOI: 10.1038/nm.4079] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
104 Prathipati P, Nandi SS, Mishra PK. Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy. Stem Cell Rev Rep 2017;13:79-91. [PMID: 27807762 DOI: 10.1007/s12015-016-9696-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
105 Lin YH, Wu MH, Yeh CT, Lin KH. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. Int J Mol Sci. 2018;19. [PMID: 30477236 DOI: 10.3390/ijms19123742] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
106 Shibata C, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Koike K. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Molecular and Cellular Therapies. 2013;1:5. [PMID: 26056570 DOI: 10.1186/2052-8426-1-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
107 Graffmann N, Ring S, Kawala MA, Wruck W, Ncube A, Trompeter HI, Adjaye J. Modeling Nonalcoholic Fatty Liver Disease with Human Pluripotent Stem Cell-Derived Immature Hepatocyte-Like Cells Reveals Activation of PLIN2 and Confirms Regulatory Functions of Peroxisome Proliferator-Activated Receptor Alpha. Stem Cells Dev. 2016;25:1119-1133. [PMID: 27308945 DOI: 10.1089/scd.2015.0383] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
108 Vliegenthart AD, Antoine DJ, Dear JW. Target biomarker profile for the clinical management of paracetamol overdose. Br J Clin Pharmacol 2015;80:351-62. [PMID: 26076366 DOI: 10.1111/bcp.12699] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
109 Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3-14. [PMID: 25979468 DOI: 10.1016/j.addr.2015.05.001] [Cited by in Crossref: 633] [Cited by in F6Publishing: 622] [Article Influence: 90.4] [Reference Citation Analysis]
110 Teng KY, Barajas JM, Hu P, Jacob ST, Ghoshal K. Role of B Cell Lymphoma 2 in the Regulation of Liver Fibrosis in miR-122 Knockout Mice. Biology (Basel) 2020;9:E157. [PMID: 32650615 DOI: 10.3390/biology9070157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Fernández-Hernando C, Baldán A. MicroRNAs and Cardiovascular Disease. Curr Genet Med Rep 2013;1:30-8. [PMID: 24563824 DOI: 10.1007/s40142-013-0008-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
112 Kang HY, Choi YK, Jeong YI, Choi KC, Hyun SH, Hwang WS, Jeung EB. Immortalization of Porcine 11β-Hydroxysteroid Dehydrogenase Type 1-Transgenic Liver Cells Using SV40 Large T Antigen. Int J Mol Sci 2017;18:E2625. [PMID: 29206210 DOI: 10.3390/ijms18122625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
113 Telichko AV, Wang H, Bachawal S, Kumar SU, Bose JC, Paulmurugan R, Dahl JJ. Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma. Ultrasound Med Biol 2021;47:309-22. [PMID: 33153807 DOI: 10.1016/j.ultrasmedbio.2020.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
114 Li LJ, Chang WM, Hsiao M. Aberrant Expression of microRNA Clusters in Head and Neck Cancer Development and Progression: Current and Future Translational Impacts. Pharmaceuticals (Basel) 2021;14:194. [PMID: 33673471 DOI: 10.3390/ph14030194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9:e107986. [PMID: 25238238 DOI: 10.1371/journal.pone.0107986] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 13.1] [Reference Citation Analysis]
116 Peters LJF, Biessen EAL, Hohl M, Weber C, van der Vorst EPC, Santovito D. Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease. Front Physiol 2020;11:793. [PMID: 32733281 DOI: 10.3389/fphys.2020.00793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
117 Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542-552. [PMID: 23689081 DOI: 10.1038/nrgastro.2013.87] [Cited by in Crossref: 367] [Cited by in F6Publishing: 361] [Article Influence: 40.8] [Reference Citation Analysis]
118 Damas ND, Fossat N, Scheel TKH. Functional Interplay between RNA Viruses and Non-Coding RNA in Mammals. Noncoding RNA 2019;5:E7. [PMID: 30646609 DOI: 10.3390/ncrna5010007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
119 Beger RD, Bhattacharyya S, Yang X, Gill PS, Schnackenberg LK, Sun J, James LP. Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol 2015;89:1497-522. [PMID: 25983262 DOI: 10.1007/s00204-015-1519-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
120 Chang Y, Han JA, Kang SM, Jeong SW, Ryu T, Park HS, Yoo JJ, Lee SH, Kim SG, Kim YS, Kim HS, Jin SY, Ryu S, Jang JY. Clinical impact of serum exosomal microRNA in liver fibrosis. PLoS One 2021;16:e0255672. [PMID: 34506494 DOI: 10.1371/journal.pone.0255672] [Reference Citation Analysis]
121 Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407. [PMID: 24800233 DOI: 10.1155/2014/486407] [Cited by in Crossref: 37] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
122 Diab T, Hanoun N, Bureau C, Christol C, Buscail L, Cordelier P, Torrisani J. The Role of the 3' Untranslated Region in the Post-Transcriptional Regulation of KLF6 Gene Expression in Hepatocellular Carcinoma. Cancers (Basel) 2013;6:28-41. [PMID: 24378751 DOI: 10.3390/cancers6010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Baselga-Escudero L, Blade C, Ribas-Latre A, Casanova E, Suárez M, Torres JL, Salvadó MJ, Arola L, Arola-Arnal A. Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells. Nucleic Acids Res 2014;42:882-92. [PMID: 24165878 DOI: 10.1093/nar/gkt1011] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
124 Ha SY, Yu JI, Choi C, Kang SY, Joh JW, Paik SW, Kim S, Kim M, Park HC, Park CK. Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma. Sci Rep 2019;9:14738. [PMID: 31611609 DOI: 10.1038/s41598-019-50594-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
125 Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One. 2014;9:e81730. [PMID: 24416131 DOI: 10.1371/journal.pone.0081730] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
126 Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF, Wang HY. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Med Oncol 2014;31:844. [PMID: 24464213 DOI: 10.1007/s12032-014-0844-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
127 Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K, Szabo G. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532-541. [PMID: 25040043 DOI: 10.1111/liv.12633] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 10.0] [Reference Citation Analysis]
128 Novák J, Bienertová-Vašků J, Kára T, Novák M. MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators Inflamm 2014;2014:275867. [PMID: 24876669 DOI: 10.1155/2014/275867] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
129 El-Diwany R, Wasilewski LN, Witwer KW, Bailey JR, Page K, Ray SC, Cox AL, Thomas DL, Balagopal A. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. J Virol 2015;89:9454-64. [PMID: 26157120 DOI: 10.1128/JVI.00955-15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
130 Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, Bonkovsky HL, Bishop CE. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One. 2018;13:e0200847. [PMID: 30024933 DOI: 10.1371/journal.pone.0200847] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
131 Tsai TY, Wang WT, Li HK, Chen WJ, Tsai YH, Chao CH, Wu Lee YH. RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP. Sci Rep 2017;7:41452. [PMID: 28128295 DOI: 10.1038/srep41452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
132 Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. World J Gastroenterol 2014; 20(2): 333-345 [PMID: 24574704 DOI: 10.3748/wjg.v20.i2.333] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
133 Gómez de Cedrón M, Ramírez de Molina A. Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism. J Lipid Res 2016;57:193-206. [PMID: 26630911 DOI: 10.1194/jlr.R061812] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
134 Wu Z, Huang S, Zheng X, Gu S, Xu Q, Gong Y, Zhang J, Fu B, Tang L. Regulatory long non-coding RNAs of hepatic stellate cells in liver fibrosis (Review). Exp Ther Med 2021;21:351. [PMID: 33732324 DOI: 10.3892/etm.2021.9782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Shin BC, Ghosh S, Dai Y, Byun SY, Calkins KL, Devaskar SU. Early life high-fat diet exposure maintains glucose tolerance and insulin sensitivity with a fatty liver and small brain size in the adult offspring. Nutr Res 2019;69:67-81. [PMID: 31639589 DOI: 10.1016/j.nutres.2019.08.004] [Reference Citation Analysis]
136 Hu M, Huang X, Han X, Ji L. Loss of HNF1α Function Contributes to Hepatocyte Proliferation and Abnormal Cholesterol Metabolism via Downregulating miR-122: A Novel Mechanism of MODY3. Diabetes Metab Syndr Obes 2020;13:627-39. [PMID: 32184642 DOI: 10.2147/DMSO.S236915] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Wei XY, Ding J, Tian WG, Yu YC. MicroRNA-122 as a diagnostic biomarker for hepatocellular carcinoma related to hepatitis C virus: a meta-analysis and systematic review. J Int Med Res. 2020;48:300060520941634. [PMID: 32790532 DOI: 10.1177/0300060520941634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
138 Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, Gandhi CR, Li S. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol. 2013;58:522-528. [PMID: 23178710 DOI: 10.1016/j.jhep.2012.11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Wang H, Ellipilli S, Lee WJ, Li X, Vieweger M, Ho YS, Guo P. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release 2021;330:173-84. [PMID: 33316298 DOI: 10.1016/j.jconrel.2020.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
140 Robertson KA, Ghazal P. Interferon Control of the Sterol Metabolic Network: Bidirectional Molecular Circuitry-Mediating Host Protection. Front Immunol 2016;7:634. [PMID: 28066443 DOI: 10.3389/fimmu.2016.00634] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
141 Ande SR, Nguyen KH, Grégoire Nyomba BL, Mishra S. Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC. Sci Rep 2016;6:23608. [PMID: 27005704 DOI: 10.1038/srep23608] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
142 Fernández-Hernando C, Ramírez CM, Goedeke L, Suárez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013;33:178-85. [PMID: 23325474 DOI: 10.1161/ATVBAHA.112.300144] [Cited by in Crossref: 164] [Cited by in F6Publishing: 101] [Article Influence: 18.2] [Reference Citation Analysis]
143 Zeng C, Wang YL, Xie C, Sang Y, Li TJ, Zhang M, Wang R, Zhang Q, Zheng L, Zhuang SM. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 2015;6:12224-33. [PMID: 25909171 DOI: 10.18632/oncotarget.3652] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
144 Zhou Y, Sun L, Wang X, Zhou L, Li J, Liu M, Wang F, Peng J, Gui X, Zhao H, Reichenbach N, Zhou D, Ho WZ. Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs. J Neuroimmune Pharmacol 2015;10:102-10. [PMID: 25572448 DOI: 10.1007/s11481-014-9577-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
145 Zhu M, Huang Z, Zhu D, Zhou X, Shan X, Qi LW, Wu L, Cheng W, Zhu J, Zhang L, Zhang H, Chen Y, Zhu W, Wang T, Liu P. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 2017;8:17081-91. [PMID: 28177881 DOI: 10.18632/oncotarget.15059] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 13.2] [Reference Citation Analysis]
146 Otsuka M, Kishikawa T, Yoshikawa T, Yamagami M, Ohno M, Takata A, Shibata C, Ishibashi R, Koike K. MicroRNAs and liver disease. J Hum Genet. 2017;62:75-80. [PMID: 27225852 DOI: 10.1038/jhg.2016.53] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
147 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
148 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
149 Li S, Yao J, Xie M, Liu Y, Zheng M. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J Hematol Oncol 2018;11:54. [PMID: 29642941 DOI: 10.1186/s13045-018-0579-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
150 Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J, Meng S. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 2016;7:17021-17034. [PMID: 26933995 DOI: 10.18632/oncotarget.7740] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
151 Wangensteen KJ, Chang KM. Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:27-37. [PMID: 32737895 DOI: 10.1002/hep.31481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Fornari F, Gramantieri L, Callegari E, Shankaraiah RC, Piscaglia F, Negrini M, Giovannini C. MicroRNAs in Animal Models of HCC. Cancers (Basel) 2019;11:E1906. [PMID: 31805631 DOI: 10.3390/cancers11121906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
153 Teng KY, Ghoshal K. Role of Noncoding RNAs as Biomarker and Therapeutic Targets for Liver Fibrosis. Gene Expr 2015;16:155-62. [PMID: 26637395 DOI: 10.3727/105221615X14399878166078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
154 Shirvani-Dastgerdi E, Schwartz RE, Ploss A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol 2016;20:1-10. [PMID: 27504999 DOI: 10.1016/j.coviro.2016.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
155 Androsavich JR, Chau BN. Non-inhibited miRNAs shape the cellular response to anti-miR. Nucleic Acids Res 2014;42:6945-55. [PMID: 24810853 DOI: 10.1093/nar/gku344] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
156 Yang Z, Cappello T, Wang L. Emerging role of microRNAs in lipid metabolism. Acta Pharm Sin B 2015;5:145-50. [PMID: 26579440 DOI: 10.1016/j.apsb.2015.01.002] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 12.9] [Reference Citation Analysis]
157 Gan L, Xiang W, Xie B, Yu L. Molecular mechanisms of fatty liver in obesity. Front Med 2015;9:275-87. [PMID: 26290284 DOI: 10.1007/s11684-015-0410-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
158 Zhu L, Yu T, Qi X, Yang B, Shi L, Luo H, He X, Huang K, Xu W. miR-122 plays an important role in ochratoxin A-induced hepatocyte apoptosis in vitro and in vivo. Toxicol Res (Camb) 2016;5:160-7. [PMID: 30090334 DOI: 10.1039/c5tx00104h] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
159 Senís E, Mockenhaupt S, Rupp D, Bauer T, Paramasivam N, Knapp B, Gronych J, Grosse S, Windisch MP, Schmidt F, Theis FJ, Eils R, Lichter P, Schlesner M, Bartenschlager R, Grimm D. TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. Nucleic Acids Res 2017;45:e3. [PMID: 27614072 DOI: 10.1093/nar/gkw805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
160 Mishra PK, Ying W, Nandi SS, Bandyopadhyay GK, Patel KK, Mahata SK. Diabetic Cardiomyopathy: An Immunometabolic Perspective. Front Endocrinol (Lausanne) 2017;8:72. [PMID: 28439258 DOI: 10.3389/fendo.2017.00072] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
161 Zeng C, Sang Y, Wang FY, Zhuang SM. Opposing roles of C/EBPα and eEF1A1 in Sp1-regulated miR-122 transcription. RNA Biol 2020;17:202-10. [PMID: 31561740 DOI: 10.1080/15476286.2019.1673656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Andaur R, Tapia JC, Moreno J, Soto L, Armisen R, Marcelain K. Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells. Oncotarget 2018;9:26387-405. [PMID: 29899866 DOI: 10.18632/oncotarget.25405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
163 Ionescu RF, Cretoiu SM. MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy. J Med Life 2021;14:142-7. [PMID: 34104236 DOI: 10.25122/jml-2021-0071] [Reference Citation Analysis]
164 Hu B, Tang WG, Fan J, Xu Y, Sun HX. Differentially expressed miRNAs in hepatocellular carcinoma cells under hypoxic conditions are associated with transcription and phosphorylation. Oncol Lett 2018;15:467-74. [PMID: 29387230 DOI: 10.3892/ol.2017.7349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
165 Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, Lanford RE, Lemon SM. microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One. 2013;8:e76867. [PMID: 24130799 DOI: 10.1371/journal.pone.0076867] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
166 Almas I, Afzal S, Idrees M, Ashraf MU, Amin I, Shahid M, Zahid K, Zahid S. Role of circulatory microRNAs in the pathogenesis of hepatitis C virus. Virusdisease. 2017;28:360-367. [PMID: 29291226 DOI: 10.1007/s13337-017-0407-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
167 Ceccarelli S, Panera N, Gnani D, Nobili V. Dual Role of MicroRNAs in NAFLD. Int J Mol Sci. 2013;14:8437-8455. [PMID: 23594995 DOI: 10.3390/ijms14048437] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
168 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Lim E, Lim JY, Kim E, Kim YS, Shin JH, Seok PR, Jung S, Yoo SH, Kim Y. Xylobiose, an Alternative Sweetener, Ameliorates Diabetes-Related Metabolic Changes by Regulating Hepatic Lipogenesis and miR-122a/33a in db/db Mice. Nutrients 2016;8:E791. [PMID: 27929393 DOI: 10.3390/nu8120791] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
170 Qiang J, Tao YF, Bao JW, Chen J, Li HX, He J, Xu P. High Fat Diet-Induced miR-122 Regulates Lipid Metabolism and Fat Deposition in Genetically Improved Farmed Tilapia (GIFT, Oreochromis niloticus) Liver. Front Physiol 2018;9:1422. [PMID: 30344495 DOI: 10.3389/fphys.2018.01422] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
171 Basu S, Bhattacharyya SN. Insulin-like growth factor-1 prevents miR-122 production in neighbouring cells to curtail its intercellular transfer to ensure proliferation of human hepatoma cells. Nucleic Acids Res. 2014;42:7170-7185. [PMID: 24813441 DOI: 10.1093/nar/gku346] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
172 Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016;10:394-406. [PMID: 26683320 DOI: 10.1007/s12072-015-9689-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
173 He L, Tian DA, Li PY, He XX. Mouse models of liver cancer: Progress and recommendations. Oncotarget 2015;6:23306-22. [PMID: 26259234 DOI: 10.18632/oncotarget.4202] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
174 Yang YM, Kim SY, Seki E. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019;39:26-42. [PMID: 30809789 DOI: 10.1055/s-0038-1676806] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 18.7] [Reference Citation Analysis]
175 Nassirpour R, Mehta PP, Yin MJ. miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One 2013;8:e79655. [PMID: 24244539 DOI: 10.1371/journal.pone.0079655] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 6.3] [Reference Citation Analysis]
176 Singh S, de Ronde MWJ, Kok MGM, Beijk MA, De Winter RJ, van der Wal AC, Sondermeijer BM, Meijers JCM, Creemers EE, Pinto-Sietsma SJ. MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart. 2020;7. [PMID: 32487772 DOI: 10.1136/openhrt-2019-001223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
177 Huang R, Duan X, Fan J, Li G, Wang B. Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8690592. [PMID: 30931332 DOI: 10.1155/2019/8690592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
178 Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167-1178. [PMID: 24039437 DOI: 10.2147/ott.s36161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
179 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol. 2015;36:4773-4776. [PMID: 25636448 DOI: 10.1007/s13277-015-3128-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
181 Murakami Y, Toyoda H, Tanahashi T, Tanaka J, Kumada T, Yoshioka Y, Kosaka N, Ochiya T, Taguchi YH. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One. 2012;7:e48366. [PMID: 23152743 DOI: 10.1371/journal.pone.0048366] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 10.8] [Reference Citation Analysis]
182 Liu X, Zhao J, Liu Q, Xiong X, Zhang Z, Jiao Y, Li X, Liu B, Li Y, Lu Y. MicroRNA-124 promotes hepatic triglyceride accumulation through targeting tribbles homolog 3. Sci Rep. 2016;6:37170. [PMID: 27845424 DOI: 10.1038/srep37170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
183 Willeit P, Skroblin P, Kiechl S, Fernández-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 2016;37:3260-6. [PMID: 27099265 DOI: 10.1093/eurheartj/ehw146] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
184 Valdmanis PN, Kim HK, Chu K, Zhang F, Xu J, Munding EM, Shen J, Kay MA. miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression. Nat Commun 2018;9:5321. [PMID: 30552326 DOI: 10.1038/s41467-018-07786-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
185 Mennigen JA, Martyniuk CJ, Seiliez I, Panserat S, Skiba-Cassy S. Metabolic consequences of microRNA-122 inhibition in rainbow trout, Oncorhynchus mykiss. BMC Genomics 2014;15:70. [PMID: 24467738 DOI: 10.1186/1471-2164-15-70] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
186 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
187 Bei C, Liu S, Yu X, Qiu M, Tang B, Liao W, He S, Yu H. Single Nucleotide Polymorphisms in miR-122 Are Associated with the Risk of Hepatocellular Carcinoma in a Southern Chinese Population. Biomed Res Int 2018;2018:1540201. [PMID: 30662901 DOI: 10.1155/2018/1540201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
188 Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology. 2013;58:1681-1692. [PMID: 23703729 DOI: 10.1002/hep.26514] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
189 Raitoharju E, Seppälä I, Lyytikäinen LP, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, Klopp N, Illig T, Leiviskä J, Loo BM, Oksala N, Kähönen M, Hutri-Kähönen N, Laaksonen R, Raitakari O, Lehtimäki T. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep 2016;6:38262. [PMID: 27917915 DOI: 10.1038/srep38262] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
190 Tomasetti M, Amati M, Santarelli L, Neuzil J. MicroRNA in Metabolic Re-Programming and Their Role in Tumorigenesis. Int J Mol Sci 2016;17:E754. [PMID: 27213336 DOI: 10.3390/ijms17050754] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
191 Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci 2021;22:7716. [PMID: 34299336 DOI: 10.3390/ijms22147716] [Reference Citation Analysis]
192 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-665. [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183] [Cited by in Crossref: 559] [Cited by in F6Publishing: 528] [Article Influence: 62.1] [Reference Citation Analysis]
193 Li Z, Zhou Y, Zhang L, Jia K, Wang S, Wang M, Li N, Yu Y, Cao X, Hou J. microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4. Oncogenesis 2020;9:95. [PMID: 33099584 DOI: 10.1038/s41389-020-00282-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
194 Singh AK, Aryal B, Zhang X, Fan Y, Price NL, Suárez Y, Fernández-Hernando C. Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins. Semin Cell Dev Biol 2018;81:129-40. [PMID: 29183708 DOI: 10.1016/j.semcdb.2017.11.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
195 Adams RL, Pirakitikulr N, Pyle AM. Functional RNA structures throughout the Hepatitis C Virus genome. Curr Opin Virol 2017;24:79-86. [PMID: 28511116 DOI: 10.1016/j.coviro.2017.04.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
196 Mann DA. Epigenetics in liver disease. Hepatology 2014;60:1418-25. [PMID: 24633972 DOI: 10.1002/hep.27131] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 11.5] [Reference Citation Analysis]
197 Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 2017;16:312-22. [PMID: 27980102 DOI: 10.1158/1535-7163.MCT-16-0124] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
198 He Z, Hu C, Jia W. miRNAs in non-alcoholic fatty liver disease. Front Med. 2016;10:389-396. [PMID: 27680976 DOI: 10.1007/s11684-016-0468-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
199 Pratama MY, Pascut D, Massi MN, Tiribelli C. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med 2019;7:577. [PMID: 31807558 DOI: 10.21037/atm.2019.09.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
200 Yang YM, Lee CG, Koo JH, Kim TH, Lee JM, An J, Kim KM, Kim SG. Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction. Oncotarget 2015;6:19055-69. [PMID: 25965999 DOI: 10.18632/oncotarget.3957] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
201 Valencia-Quintana R, Sánchez-Alarcón J, Tenorio-Arvide MG, Deng Y, Montiel-González JM, Gómez-Arroyo S, Villalobos-Pietrini R, Cortés-Eslava J, Flores-Márquez AR, Arenas-Huertero F. The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review. Front Microbiol 2014;5:102. [PMID: 24672518 DOI: 10.3389/fmicb.2014.00102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
202 Liu SY. Abnormal regulation of non-coding RNAs plays a role in development and progression of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1107-1113 [DOI: 10.11569/wcjd.v27.i18.1107] [Reference Citation Analysis]
203 Kishikawa T, Otsuka M, Tan PS, Ohno M, Sun X, Yoshikawa T, Shibata C, Takata A, Kojima K, Takehana K, Ohishi M, Ota S, Noyama T, Kondo Y, Sato M, Soga T, Hoshida Y, Koike K. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 2015;6:8339-52. [PMID: 25826076 DOI: 10.18632/oncotarget.3234] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
204 Bansode RR, Khatiwada JR, Losso JN, Williams LL. Targeting MicroRNA in Cancer Using Plant-Based Proanthocyanidins. Diseases 2016;4:E21. [PMID: 28933401 DOI: 10.3390/diseases4020021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
205 Cao H, Yu W, Li X, Wang J, Gao S, Holton NE, Eliason S, Sharp T, Amendt BA. A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent. Gene Ther 2016;23:527-42. [PMID: 26934100 DOI: 10.1038/gt.2016.22] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
206 Bartel DP. Metazoan MicroRNAs. Cell 2018;173:20-51. [PMID: 29570994 DOI: 10.1016/j.cell.2018.03.006] [Cited by in Crossref: 1203] [Cited by in F6Publishing: 1095] [Article Influence: 401.0] [Reference Citation Analysis]
207 Saliani N, Montazersaheb S, Montasser Kouhsari S. Micromanaging Glucose Tolerance and Diabetes. Adv Pharm Bull 2017;7:547-56. [PMID: 29399544 DOI: 10.15171/apb.2017.066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
208 Chen E, Xu X, Liu R, Liu T. Small but Heavy Role: MicroRNAs in Hepatocellular Carcinoma Progression. Biomed Res Int 2018;2018:6784607. [PMID: 29951542 DOI: 10.1155/2018/6784607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
209 Ono C, Fukuhara T, Motooka D, Nakamura S, Okuzaki D, Yamamoto S, Tamura T, Mori H, Sato A, Uemura K, Fauzyah Y, Kurihara T, Suda T, Nishio A, Hmwe SS, Okamoto T, Tatsumi T, Takehara T, Chayama K, Wakita T, Koike K, Matsuura Y. Characterization of miR-122-independent propagation of HCV. PLoS Pathog 2017;13:e1006374. [PMID: 28494029 DOI: 10.1371/journal.ppat.1006374] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
210 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
211 Zhang Y, Huang W, Ran Y, Xiong Y, Zhong Z, Fan X, Wang Z, Ye Q. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol 2015;36:8309-16. [PMID: 26002580 DOI: 10.1007/s13277-015-3582-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
212 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Amacher DE, Schomaker SJ, Aubrecht J. Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics. Mol Diagn Ther 2013;17:343-54. [PMID: 23868512 DOI: 10.1007/s40291-013-0049-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
214 Baldán Á, de Aguiar Vallim TQ. miRNAs and High-Density Lipoprotein metabolism. Biochim Biophys Acta 2016;1861:2053-61. [PMID: 26869447 DOI: 10.1016/j.bbalip.2016.01.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
215 Suzuki T, Kikuguchi C, Nishijima S, Nagashima T, Takahashi A, Okada M, Yamamoto T. Postnatal liver functional maturation requires Cnot complex-mediated decay of mRNAs encoding cell cycle and immature liver genes. Development 2019;146:dev168146. [PMID: 30733279 DOI: 10.1242/dev.168146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
216 Lockard RD, Wilson ME, Rodríguez NE. Sex-Related Differences in Immune Response and Symptomatic Manifestations to Infection with Leishmania Species. J Immunol Res 2019;2019:4103819. [PMID: 30756088 DOI: 10.1155/2019/4103819] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
217 Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018;17:35-56. [PMID: 28935918 DOI: 10.1038/nrd.2017.162] [Cited by in Crossref: 239] [Cited by in F6Publishing: 213] [Article Influence: 47.8] [Reference Citation Analysis]
218 van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851-864. [PMID: 24935956 DOI: 10.15252/emmm.201100899] [Cited by in Crossref: 385] [Cited by in F6Publishing: 354] [Article Influence: 55.0] [Reference Citation Analysis]
219 Yang N, Li S, Li G, Zhang S, Tang X, Ni S, Jian X, Xu C, Zhu J, Lu M. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8:3683-3695. [PMID: 27713136 DOI: 10.18632/oncotarget.12465] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
220 Cossiga V, Lembo V, Nigro C, Mirra P, Miele C, D'Argenio V, Leone A, Mazzone G, Veneruso I, Guido M, Beguinot F, Caporaso N, Morisco F. The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. Nutrients 2021;13:1281. [PMID: 33924725 DOI: 10.3390/nu13041281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology. 2015;61:141-152. [PMID: 25131933 DOI: 10.1002/hep.27379] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
222 Zhang Y, Tan YY, Chen PP, Xu H, Xie SJ, Xu SJ, Li B, Li JH, Liu S, Yang JH, Zhou H, Qu LH. Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development. Cell Death Dis 2021;12:1161. [PMID: 34907157 DOI: 10.1038/s41419-021-04436-7] [Reference Citation Analysis]
223 Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM. Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. Oncotarget 2018;9:17238-54. [PMID: 29682219 DOI: 10.18632/oncotarget.24428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
224 Szabo G, Satishchandran A. MicroRNAs in alcoholic liver disease. Semin Liver Dis. 2015;35:36-42. [PMID: 25632933 DOI: 10.1055/s-0034- 1397347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5(9): 479-486 [PMID: 24073299 DOI: 10.4254/wjh.v5.i9.479] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
226 Li HK, Mai RT, Huang HD, Chou CH, Chang YA, Chang YW, You LR, Chen CM, Lee YH. DDX3 Represses Stemness by Epigenetically Modulating Tumor-suppressive miRNAs in Hepatocellular Carcinoma. Sci Rep 2016;6:28637. [PMID: 27344963 DOI: 10.1038/srep28637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
227 Gupta A, Swaminathan G, Martin-Garcia J, Navas-Martin S. MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses 2012;4:2485-513. [PMID: 23202492 DOI: 10.3390/v4112485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
228 Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2015;10:25-52. [PMID: 26819546 DOI: 10.4137/bmi.s29512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
229 Zhou N, Wu J, Wang X, Sun Z, Han Q, Zhao L. Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumour Biol. 2016;37:2145-2152. [PMID: 26349912 DOI: 10.1007/s13277-015-3841-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
230 Szabo G, Satishchandran A. MicroRNAs in alcoholic liver disease. Semin Liver Dis 2015;35:36-42. [PMID: 25632933 DOI: 10.1055/s-0034-1397347] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
231 Kim GW, Lee SH, Cho H, Kim M, Shin EC, Oh JW. Hepatitis C Virus Core Protein Promotes miR-122 Destabilization by Inhibiting GLD-2. PLoS Pathog 2016;12:e1005714. [PMID: 27366906 DOI: 10.1371/journal.ppat.1005714] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
232 Sedano CD, Sarnow P. Interaction of host cell microRNAs with the HCV RNA genome during infection of liver cells. Semin Liver Dis 2015;35:75-80. [PMID: 25632937 DOI: 10.1055/s-0034-1397351] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
233 Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, Tan BC. MiR-31-5p-ACOX1 Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory Prostaglandin E2. Theranostics 2018;8:486-504. [PMID: 29290822 DOI: 10.7150/thno.22059] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
234 Chowdhary V, Teng KY, Thakral S, Zhang B, Lin CH, Wani N, Bruschweiler-Li L, Zhang X, James L, Yang D, Junge N, Brüschweiler R, Lee WM, Ghoshal K. miRNA-122 Protects Mice and Human Hepatocytes from Acetaminophen Toxicity by Regulating Cytochrome P450 Family 1 Subfamily A Member 2 and Family 2 Subfamily E Member 1 Expression. Am J Pathol 2017;187:2758-74. [PMID: 28963035 DOI: 10.1016/j.ajpath.2017.08.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
235 Capuani B, Pacifici F, Della-Morte D, Lauro D. Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs. Front Endocrinol (Lausanne) 2018;9:719. [PMID: 30581418 DOI: 10.3389/fendo.2018.00719] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
236 Zheng B, Jeong S, Zhu Y, Chen L, Xia Q. miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA). Oncotarget. 2017;8:100819-100830. [PMID: 29246025 DOI: 10.18632/oncotarget.19044] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
237 Zheng Y, Jiang S, Zhang Y, Zhang R, Gong D. Detection of miR-33 Expression and the Verification of Its Target Genes in the Fatty Liver of Geese. Int J Mol Sci 2015;16:12737-52. [PMID: 26057744 DOI: 10.3390/ijms160612737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
238 Lendvai G, Szekerczés T, Kontsek E, Selvam A, Szakos A, Schaff Z, Björnstedt M, Kiss A. The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines. Pathol Oncol Res 2020;26:2669-81. [PMID: 32656599 DOI: 10.1007/s12253-020-00870-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 de Oliveira LF, de Andrade AAS, Pagliari C, de Carvalho LV, Silveira TS, Cardoso JF, Silva ALTE, de Vasconcelos JM, Moreira-Nunes CA, Burbano RMR, Nunes MRT, Dos Santos EJM, Júnior JLDSGV. Differential expression analysis and profiling of hepatic miRNA and isomiRNA in dengue hemorrhagic fever. Sci Rep 2021;11:5554. [PMID: 33692368 DOI: 10.1038/s41598-020-72892-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
241 Zhao B, Zhou B, Shi K, Zhang R, Dong C, Xie D, Tang L, Tian Y, Qian Z, Yang L. Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy. Cancer Sci 2021;112:2481-92. [PMID: 33792132 DOI: 10.1111/cas.14903] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Housden BE, Muhar M, Gemberling M, Gersbach CA, Stainier DY, Seydoux G, Mohr SE, Zuber J, Perrimon N. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat Rev Genet 2017;18:24-40. [PMID: 27795562 DOI: 10.1038/nrg.2016.118] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 17.2] [Reference Citation Analysis]
243 Mitash N, E Donovan J, Swiatecka-Urban A. The Role of MicroRNA in the Airway Surface Liquid Homeostasis. Int J Mol Sci 2020;21:E3848. [PMID: 32481719 DOI: 10.3390/ijms21113848] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
244 Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, He DX, Tang SS, Wei H, Yu CY. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2019;11:10578-88. [PMID: 30802029 DOI: 10.1021/acsami.9b00634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
245 Pawlotsky JM. Hepatitis: MicroRNA antagonists: promising antiviral agents against HCV and other viruses? Nat Rev Gastroenterol Hepatol 2017;14:264-6. [PMID: 28293028 DOI: 10.1038/nrgastro.2017.28] [Reference Citation Analysis]
246 Wang X, Yu B, Ren W, Mo X, Zhou C, He H, Jia H, Wang L, Jacob ST, Lee RJ, Ghoshal K, Lee LJ. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control Release 2013;172:690-8. [PMID: 24121065 DOI: 10.1016/j.jconrel.2013.09.027] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
247 Yang W, Chen J, Meng Y, Chen Z, Yang J. Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver. Int J Mol Sci 2018;19:E1302. [PMID: 29701719 DOI: 10.3390/ijms19051302] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
248 Barajas JM, Reyes R, Guerrero MJ, Jacob ST, Motiwala T, Ghoshal K. The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep. 2018;8:9105. [PMID: 29904144 DOI: 10.1038/s41598-018-27358-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
249 Adlakha YK, Saini N. MicroRNA: a connecting road between apoptosis and cholesterol metabolism. Tumour Biol 2016;37:8529-54. [PMID: 27105614 DOI: 10.1007/s13277-016-4988-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
250 He J, Wang W, Lu L, Tian Y, Niu D, Ren J, Dong L, Sun S, Zhao Y, Chen L, Shen J, Li X. Analysis of miRNAs and their target genes associated with lipid metabolism in duck liver. Sci Rep 2016;6:27418. [PMID: 27272010 DOI: 10.1038/srep27418] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
251 Vogt J, Sheinson D, Katavolos P, Irimagawa H, Tseng M, Alatsis KR, Proctor WR. Variance component analysis of circulating miR-122 in serum from healthy human volunteers. PLoS One 2019;14:e0220406. [PMID: 31348817 DOI: 10.1371/journal.pone.0220406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
252 Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, Furukawa H, Abiru S, Yamasaki K, Nagaoka S, Hashimoto S, Bekki S, Kamitsukasa H, Nakamura Y, Ohta H, Shimada M, Takahashi H, Mita E, Hijioka T, Yamashita H, Kouno H, Nakamuta M, Ario K, Muro T, Sakai H, Sugi K, Nishimura H, Yoshizawa K, Sato T, Naganuma A, Komatsu T, Oohara Y, Makita F, Tomizawa M, Yatsuhashi H. Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis. PLoS One. 2015;10:e0136908. [PMID: 26575387 DOI: 10.1371/journal.pone.0136908] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
253 Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Jacobson IM, Rice CM, Darnell RB. Hepatitis C virus RNA functionally sequesters miR-122. Cell. 2015;160:1099-1110. [PMID: 25768906 DOI: 10.1016/j.cell.2015.02.025] [Cited by in Crossref: 232] [Cited by in F6Publishing: 211] [Article Influence: 33.1] [Reference Citation Analysis]
254 Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, Ye H, Zheng S, Wei L, Deng X, Chen R, Zhou J. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159-170. [PMID: 30195653 DOI: 10.1016/j.ebiom.2018.08.055] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
255 Alzahrani FA, El-Magd MA, Abdelfattah-Hassan A, Saleh AA, Saadeldin IM, El-Shetry ES, Badawy AA, Alkarim S. Potential Effect of Exosomes Derived from Cancer Stem Cells and MSCs on Progression of DEN-Induced HCC in Rats.Stem Cells Int. 2018;2018:8058979. [PMID: 30224923 DOI: 10.1155/2018/8058979] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
256 Brzuzan P, Florczyk M, Łakomiak A, Woźny M. Illumina Sequencing Reveals Aberrant Expression of MicroRNAs and Their Variants in Whitefish (Coregonus lavaretus) Liver after Exposure to Microcystin-LR. PLoS One 2016;11:e0158899. [PMID: 27391076 DOI: 10.1371/journal.pone.0158899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
257 Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci 2015;16:924-49. [PMID: 25561239 DOI: 10.3390/ijms16010924] [Cited by in Crossref: 193] [Cited by in F6Publishing: 184] [Article Influence: 27.6] [Reference Citation Analysis]
258 Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab 2021;50:101111. [PMID: 33160101 DOI: 10.1016/j.molmet.2020.101111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
259 Song K, Kwon H, Han C, Zhang J, Dash S, Lim K, Wu T. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122. Oncotarget 2015;6:40822-35. [PMID: 26506419 DOI: 10.18632/oncotarget.5812] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
260 Kostyniuk DJ, Marandel L, Jubouri M, Dias K, de Souza RF, Zhang D, Martyniuk CJ, Panserat S, Mennigen JA. Profiling the rainbow trout hepatic miRNAome under diet-induced hyperglycemia. Physiol Genomics 2019;51:411-31. [PMID: 31282806 DOI: 10.1152/physiolgenomics.00032.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
261 Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, Liu Y. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8:122. [PMID: 26514126 DOI: 10.1186/s13045-015-0220-7] [Cited by in Crossref: 283] [Cited by in F6Publishing: 297] [Article Influence: 40.4] [Reference Citation Analysis]
262 Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira Ò, Gironès J, Ricart W, Fernández-Real JM, Ortega FJ. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes (Lond) 2017;41:620-30. [PMID: 28119530 DOI: 10.1038/ijo.2017.21] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
263 Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M, Liu Y. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis. J Cell Mol Med. 2017;21:2963-2973. [PMID: 28544786 DOI: 10.1111/jcmm.13208] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 15.4] [Reference Citation Analysis]
264 Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol 2021;2021:8837811. [PMID: 33728291 DOI: 10.1155/2021/8837811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
265 Zhao LX, Zhang K, Shen BB, Li JN. Mesenchymal stem cell-derived exosomes for gastrointestinal cancer. World J Gastrointest Oncol 2021; 13(12): 1981-1996 [DOI: 10.4251/wjgo.v13.i12.1981] [Reference Citation Analysis]
266 Chen S, Chen D, Yang H, Wang X, Wang J, Xu C. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. BMC Gastroenterol. 2020;20:39. [PMID: 32070295 DOI: 10.1186/s12876-020-01189-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
267 Zhang Q, Sun X, Xiao X, Zheng J, Li M, Yu M, Ping F, Wang Z, Qi C, Wang T, Wang X. Maternal chromium restriction induces insulin resistance in adult mice offspring through miRNA. Int J Mol Med 2018;41:1547-59. [PMID: 29286159 DOI: 10.3892/ijmm.2017.3328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
268 Ward DM, Shodeinde AB, Peppas NA. Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment. Adv Healthc Mater 2021;10:e2100350. [PMID: 33973393 DOI: 10.1002/adhm.202100350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol 2016; 22(1): 300-325 [PMID: 26755878 DOI: 10.3748/wjg.v22.i1.300] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
270 Novák J, Olejníčková V, Tkáčová N, Santulli G. Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol 2015;887:79-100. [PMID: 26662987 DOI: 10.1007/978-3-319-22380-3_5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 11.5] [Reference Citation Analysis]
271 Goedeke L, Wagschal A, Fernández-Hernando C, Näär AM. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta 2016;1861:2047-52. [PMID: 26968099 DOI: 10.1016/j.bbalip.2016.03.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
272 Pawlotsky JM. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antiviral Res. 2014;105:22-25. [PMID: 24583032 DOI: 10.1016/j.antiviral.2014.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
273 Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012;122:2773-6. [PMID: 22820284 DOI: 10.1172/JCI63966] [Cited by in Crossref: 77] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
274 Sethupathy P. Needles in the genetic haystack of lipid disorders: single nucleotide polymorphisms in the microRNA regulome. J Lipid Res 2013;54:1168-73. [PMID: 23505316 DOI: 10.1194/jlr.R035766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
275 Dai Y, Ghosh S, Shin BC, Devaskar SU. Role of microRNA-122 in hepatic lipid metabolism of the weanling female rat offspring exposed to prenatal and postnatal caloric restriction. J Nutr Biochem 2019;73:108220. [PMID: 31630081 DOI: 10.1016/j.jnutbio.2019.108220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Itami S, Eguchi Y, Mizutani T, Aoki E, Ohgi T, Kuroda M, Ochiya T, Kato N, Suzuki HI, Kawada N, Murakami Y. Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent. Mol Ther Nucleic Acids 2015;4:e219. [PMID: 28110745 DOI: 10.1038/mtna.2014.71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
277 Zhang M, Sun W, Zhou M, Tang Y. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. Sci Rep 2017;7:14493. [PMID: 29101357 DOI: 10.1038/s41598-017-15141-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
278 Wei L, Gong X, Martinez OM, Krams SM. Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. Transpl Immunol. 2013;29:123-129. [PMID: 24001411 DOI: 10.1016/j.trim.2013.08.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
279 Mallol C, Casana E, Jimenez V, Casellas A, Haurigot V, Jambrina C, Sacristan V, Morró M, Agudo J, Vilà L, Bosch F. AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice. Mol Metab 2017;6:664-80. [PMID: 28702323 DOI: 10.1016/j.molmet.2017.05.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
280 Yang G, Zhang M, Zhao Y, Pan Y, Kan M, Li J, He K, Zhang X. HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. PLoS One 2020;15:e0230450. [PMID: 32210451 DOI: 10.1371/journal.pone.0230450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
281 Lee HM, Wong WKK, Fan B, Lau ES, Hou Y, O CK, Luk AOY, Chow EYK, Ma RCW, Chan JCN, Kong APS. Detection of increased serum miR-122-5p and miR-455-3p levels before the clinical diagnosis of liver cancer in people with type 2 diabetes. Sci Rep 2021;11:23756. [PMID: 34887498 DOI: 10.1038/s41598-021-03222-x] [Reference Citation Analysis]
282 Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, Gandhi CR, Li S. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol. 2013;58:522-528. [PMID: 23178710 DOI: 10.1016/j.jhep.2012.11.011] [Cited by in Crossref: 119] [Cited by in F6Publishing: 118] [Article Influence: 11.9] [Reference Citation Analysis]
283 Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12:23. [PMID: 28974990 DOI: 10.1186/s12263-017-0577-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
284 Israelow B, Mullokandov G, Agudo J, Sourisseau M, Bashir A, Maldonado AY, Dar AC, Brown BD, Evans MJ. Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nat Commun 2014;5:5408. [PMID: 25403145 DOI: 10.1038/ncomms6408] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
285 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. Int J Mol Sci 2018;19:E3966. [PMID: 30544653 DOI: 10.3390/ijms19123966] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
286 Li M, Tang Y, Wu L, Mo F, Wang X, Li H, Qi R, Zhang H, Srivastava A, Ling C. The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation. Blood 2017;130:1041-51. [PMID: 28655781 DOI: 10.1182/blood-2016-12-755967] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
287 Chai C, Cox B, Yaish D, Gross D, Rosenberg N, Amblard F, Shemuelian Z, Gefen M, Korach A, Tirosh O, Lanton T, Link H, Tam J, Permyakova A, Ozhan G, Citrin J, Liao H, Tannous M, Hahn M, Axelrod J, Arretxe E, Alonso C, Martinez-Arranz I, Betés PO, Safadi R, Salhab A, Amer J, Tber Z, Mengshetti S, Giladi H, Schinazi RF, Galun E. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology 2020;159:999-1014.e9. [PMID: 32450149 DOI: 10.1053/j.gastro.2020.05.056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
288 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 481] [Article Influence: 56.1] [Reference Citation Analysis]
289 Kunden RD, Khan JQ, Ghezelbash S, Wilson JA. The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle. Int J Mol Sci. 2020;21. [PMID: 32784807 DOI: 10.3390/ijms21165677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
290 Liu AM, Xu Z, Shek FH, Wong KF, Lee NP, Poon RT, Chen J, Luk JM. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS One. 2014;9:e86872. [PMID: 24466275 DOI: 10.1371/journal.pone.0086872] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
291 Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. Complexity of microRNA function and the role of isomiRs in lipid homeostasis. J Lipid Res 2013;54:1182-91. [PMID: 23505317 DOI: 10.1194/jlr.R034801] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
292 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
293 Selvam AK, Jawad R, Gramignoli R, Achour A, Salter H, Björnstedt M. A Novel mRNA-Mediated and MicroRNA-Guided Approach to Specifically Eradicate Drug-Resistant Hepatocellular Carcinoma Cell Lines by Se-Methylselenocysteine. Antioxidants (Basel) 2021;10:1094. [PMID: 34356326 DOI: 10.3390/antiox10071094] [Reference Citation Analysis]
294 Yan X, Wang Z, Bishop CA, Weitkunat K, Feng X, Tarbier M, Luo J, Friedländer MR, Burkhardt R, Klaus S, Willnow TE, Poy MN. Control of hepatic gluconeogenesis by Argonaute2. Mol Metab 2018;18:15-24. [PMID: 30348590 DOI: 10.1016/j.molmet.2018.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
295 Beavers KR, Werfel TA, Shen T, Kavanaugh TE, Kilchrist KV, Mares JW, Fain JS, Wiese CB, Vickers KC, Weiss SM, Duvall CL. Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. Adv Mater 2016;28:7984-92. [PMID: 27383910 DOI: 10.1002/adma.201601646] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
296 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292-1324. [PMID: 23698400 DOI: 10.3390/v5051292] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
297 Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol. 2015;8:4-22. [PMID: 25553076 DOI: 10.1177/1756283x14547360] [Cited by in Crossref: 99] [Cited by in F6Publishing: 55] [Article Influence: 14.1] [Reference Citation Analysis]
298 Jin X, Gao J, Zheng R, Yu M, Ren Y, Yan T, Huang Y, Li Y. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy. Cell Death Dis 2020;11:123. [PMID: 32054840 DOI: 10.1038/s41419-020-2293-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
299 Shang W, Adzika GK, Li Y, Huang Q, Ding N, Chinembiri B, Rashid MS, Machuki JO. Molecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinoma. Cancer Med 2019;8:6684-99. [PMID: 31523930 DOI: 10.1002/cam4.2553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
300 Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199-227. [PMID: 18817506 DOI: 10.1146/annurev.pathol.4.110807.092222] [Cited by in Crossref: 642] [Cited by in F6Publishing: 642] [Article Influence: 49.4] [Reference Citation Analysis]
301 Ono C, Fukuhara T, Li S, Wang J, Sato A, Izumi T, Fauzyah Y, Yamamoto T, Morioka Y, Dokholyan NV, Standley DM, Matsuura Y. Various miRNAs compensate the role of miR-122 on HCV replication. PLoS Pathog. 2020;16:e1008308. [PMID: 32574204 DOI: 10.1371/journal.ppat.1008308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
302 Góralska J, Raźny U, Polus A, Dziewońska A, Gruca A, Zdzienicka A, Dembińska-Kieć A, Solnica B, Micek A, Kapusta M, Słowińska-Solnica K, Malczewska-Malec M. Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. Nutrients 2020;12:E476. [PMID: 32069846 DOI: 10.3390/nu12020476] [Reference Citation Analysis]
303 Cheng L, Zhu Y, Han H, Zhang Q, Cui K, Shen H, Zhang J, Yan J, Prochownik E, Li Y. MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis 2017;8:e2916. [PMID: 28703810 DOI: 10.1038/cddis.2017.309] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
304 Hsu SD, Huang HY, Chou CH, Sun YM, Hsu MT, Tsou AP. Integrated analyses to reconstruct microRNA-mediated regulatory networks in mouse liver using high-throughput profiling. BMC Genomics 2015;16 Suppl 2:S12. [PMID: 25707768 DOI: 10.1186/1471-2164-16-S2-S12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
305 Bridges JP, Schehr A, Wang Y, Huo L, Besnard V, Ikegami M, Whitsett JA, Xu Y. Epithelial SCAP/INSIG/SREBP signaling regulates multiple biological processes during perinatal lung maturation. PLoS One 2014;9:e91376. [PMID: 24806461 DOI: 10.1371/journal.pone.0091376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
306 Lee CH, Kim JH, Lee SW. Prospects for nucleic acid-based therapeutics against hepatitis C virus. World J Gastroenterol 2013; 19(47): 8949-8962 [PMID: 24379620 DOI: 10.3748/wjg.v19.i47.8949] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
307 Hänninen M, Jäntti T, Tolppanen H, Segersvärd H, Tarvasmäki T, Lassus J, Vausort M, Devaux Y, Sionis A, Tikkanen I, Harjola VP, Lakkisto P, For The CardShock Study Group. Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock. Int J Mol Sci 2020;21:E7925. [PMID: 33114482 DOI: 10.3390/ijms21217925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
308 Murakami Y, Tanahashi T, Okada R, Toyoda H, Kumada T, Enomoto M, Tamori A, Kawada N, Taguchi YH, Azuma T. Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014;9:e106314. [PMID: 25215888 DOI: 10.1371/journal.pone.0106314] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
309 Shi JJ, Dang SS. Non-coding RNAs and liver diseases. Shijie Huaren Xiaohua Zazhi 2016; 24(13): 1952-1959 [DOI: 10.11569/wcjd.v24.i13.1952] [Reference Citation Analysis]
310 Fernandes J, Miranda RL, de Lemos ERS, Guterres A. MicroRNAs and Mammarenaviruses: Modulating Cellular Metabolism. Cells 2020;9:E2525. [PMID: 33238430 DOI: 10.3390/cells9112525] [Reference Citation Analysis]
311 Wang SC, Lin XL, Li J, Zhang TT, Wang HY, Shi JW, Yang S, Zhao WT, Xie RY, Wei F. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. PLoS One. 2014;9:e101330. [PMID: 24992599 DOI: 10.1371/journal.pone.0101330] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
312 Tarn WY, Cheng Y, Ko SH, Huang LM. Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics 2021;13:2015. [PMID: 34959297 DOI: 10.3390/pharmaceutics13122015] [Reference Citation Analysis]
313 Hong P, Yu M, Tian W. Diverse RNAs in adipose-derived extracellular vesicles and their therapeutic potential. Mol Ther Nucleic Acids 2021;26:665-77. [PMID: 34703651 DOI: 10.1016/j.omtn.2021.08.028] [Reference Citation Analysis]
314 Nakagawa H. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol 2015; 7(17): 2110-2118 [PMID: 26301053 DOI: 10.4254/wjh.v7.i17.2110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
315 Mullick Chowdhury S, Wang TY, Bachawal S, Devulapally R, Choe JW, Abou Elkacem L, Yakub BK, Wang DS, Tian L, Paulmurugan R, Willmann JK. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release 2016;238:272-80. [PMID: 27503707 DOI: 10.1016/j.jconrel.2016.08.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
316 Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou HI, Hoshida Y, Friedman SL. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018;69:385-95. [PMID: 29572095 DOI: 10.1016/j.jhep.2018.03.011] [Cited by in Crossref: 106] [Cited by in F6Publishing: 115] [Article Influence: 26.5] [Reference Citation Analysis]
317 Neppl RL, Wang DZ. The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. Genes Dis 2014;1:18-39. [PMID: 25328909 DOI: 10.1016/j.gendis.2014.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
318 Liu N, Jiang F, He TL, Zhang JK, Zhao J, Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, Lin TY, Cui YF. The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells. Sci Rep 2015;5:16566. [PMID: 26686459 DOI: 10.1038/srep16566] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
319 Kim KH, Lee JI, Kim OH, Hong HE, Kwak BJ, Choi HJ, Ahn J, Lee TY, Lee SC, Kim SJ. Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells. World J Stem Cells 2019; 11(11): 990-1004 [PMID: 31768225 DOI: 10.4252/wjsc.v11.i11.990] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
320 Lowey B, Hertz L, Chiu S, Valdez K, Li Q, Liang TJ. Hepatitis C Virus Infection Induces Hepatic Expression of NF-κB-Inducing Kinase and Lipogenesis by Downregulating miR-122. mBio 2019;10:e01617-19. [PMID: 31363036 DOI: 10.1128/mBio.01617-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
321 Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS One. 2014;9:e115036. [PMID: 25541689 DOI: 10.1371/journal.pone.0115036] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
322 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
323 Fatima A, Lynn DJ, O'Boyle P, Seoighe C, Morris D. The miRNAome of the postpartum dairy cow liver in negative energy balance. BMC Genomics 2014;15:279. [PMID: 24725334 DOI: 10.1186/1471-2164-15-279] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
324 Sutaria DS, Jiang J, Azevedo-Pouly AC, Wright L, Bray JA, Fredenburg K, Liu X, Lu J, Torres C, Mancinelli G, Grippo PJ, Coppola V, Schmittgen TD. Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer. Sci Rep 2019;9:11147. [PMID: 31367007 DOI: 10.1038/s41598-019-47566-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
325 Yang Y, Alderman C, Sehlaoui A, Xiao Y, Wang W. MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Can J Gastroenterol Hepatol 2018;2018:9740357. [PMID: 30046565 DOI: 10.1155/2018/9740357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
326 Li P, Chen Y, Juma CA, Yang C, Huang J, Zhang X, Zeng Y. Differential Inhibition of Target Gene Expression by Human microRNAs. Cells 2019;8:E791. [PMID: 31366019 DOI: 10.3390/cells8080791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
327 Nie YQ, Cao J, Zhou YJ, Liang X, Du YL, Wan YJ, Li YY. The effect of miRNA-122 in regulating fat deposition in a cell line model. J Cell Biochem. 2014;115:839-846. [PMID: 24288170 DOI: 10.1002/jcb.24725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
328 Vergara D, Simeone P, Franck J, Trerotola M, Giudetti A, Capobianco L, Tinelli A, Bellomo C, Fournier I, Gaballo A, Alberti S, Salzet M, Maffia M. Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. EuPA Open Proteom 2016;10:31-41. [PMID: 29900098 DOI: 10.1016/j.euprot.2016.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
329 Baran-Gale J, Kurtz CL, Erdos MR, Sison C, Young A, Fannin EE, Chines PS, Sethupathy P. Addressing Bias in Small RNA Library Preparation for Sequencing: A New Protocol Recovers MicroRNAs that Evade Capture by Current Methods. Front Genet 2015;6:352. [PMID: 26734062 DOI: 10.3389/fgene.2015.00352] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
330 Song L, Zhang Z, Zhang J, Zhu X, He L, Shi Z, Gao L, Feng F. Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice. Exp Ther Med 2016;12:889-94. [PMID: 27446292 DOI: 10.3892/etm.2016.3375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
331 Aydin Y, Kurt R, Song K, Lin D, Osman H, Youngquist B, Scott JW, Shores NJ, Thevenot P, Cohen A, Dash S. Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression. Cancers (Basel) 2019;11:E1407. [PMID: 31547152 DOI: 10.3390/cancers11101407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
332 Taniguchi K, Sugito N, Shinohara H, Kuranaga Y, Inomata Y, Komura K, Uchiyama K, Akao Y. Organ-Specific MicroRNAs (MIR122, 137, and 206) Contribute to Tissue Characteristics and Carcinogenesis by Regulating Pyruvate Kinase M1/2 (PKM) Expression. Int J Mol Sci 2018;19:E1276. [PMID: 29695138 DOI: 10.3390/ijms19051276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
333 Jun S, Datta S, Wang L, Pegany R, Cano M, Handa JT. The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE. Exp Eye Res 2019;181:346-55. [PMID: 30292489 DOI: 10.1016/j.exer.2018.09.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
334 Chen QQ, Zhang C, Qin MQ, Li J, Wang H, Xu DX, Wang JQ. Inositol-Requiring Enzyme 1 Alpha Endoribonuclease Specific Inhibitor STF-083010 Alleviates Carbon Tetrachloride Induced Liver Injury and Liver Fibrosis in Mice. Front Pharmacol 2018;9:1344. [PMID: 30538632 DOI: 10.3389/fphar.2018.01344] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
335 Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol. 2014;49:173-184. [PMID: 24258409 DOI: 10.1007/s00535-013-0909-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
336 Ju C, Wang M, Tak E, Kim B, Emontzpohl C, Yang Y, Yuan X, Kutay H, Liang Y, Hall DR, Dar WA, Bynon JS, Carmeliet P, Ghoshal K, Eltzschig HK. Hypoxia-inducible factor-1α-dependent induction of miR122 enhances hepatic ischemia tolerance. J Clin Invest 2021;131:140300. [PMID: 33792566 DOI: 10.1172/JCI140300] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Suzuki T, Adachi S, Kikuguchi C, Shibata S, Nishijima S, Kawamoto Y, Iizuka Y, Koseki H, Okano H, Natsume T, Yamamoto T. Regulation of Fetal Genes by Transitions among RNA-Binding Proteins during Liver Development. Int J Mol Sci 2020;21:E9319. [PMID: 33297405 DOI: 10.3390/ijms21239319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Khan AA, Agarwal H, Reddy SS, Arige V, Natarajan B, Gupta V, Kalyani A, Barthwal MK, Mahapatra NR. MicroRNA 27a Is a Key Modulator of Cholesterol Biosynthesis. Mol Cell Biol 2020;40:e00470-19. [PMID: 32071155 DOI: 10.1128/MCB.00470-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
339 Baselga-Escudero L, Arola-Arnal A, Pascual-Serrano A, Ribas-Latre A, Casanova E, Salvadó MJ, Arola L, Blade C. Chronic administration of proanthocyanidins or docosahexaenoic acid reverses the increase of miR-33a and miR-122 in dyslipidemic obese rats. PLoS One 2013;8:e69817. [PMID: 23922812 DOI: 10.1371/journal.pone.0069817] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 6.2] [Reference Citation Analysis]
340 Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5. [PMID: 27239288 DOI: 10.12688/f1000research.6946.1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 11.7] [Reference Citation Analysis]
341 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 11.4] [Reference Citation Analysis]
342 Laffont B, Rayner KJ. MicroRNAs in the Pathobiology and Therapy of Atherosclerosis. Can J Cardiol. 2017;33:313-324. [PMID: 28232017 DOI: 10.1016/j.cjca.2017.01.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 16.2] [Reference Citation Analysis]
343 Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287-314. [PMID: 24079833 DOI: 10.1146/annurev-pathol- 012513-104715] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Shah N, Nelson JE, Kowdley KV. MicroRNAs in Liver Disease: Bench to Bedside. J Clin Exp Hepatol. 2013;3:231-242. [PMID: 25755505 DOI: 10.1016/j.jceh.2013.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
345 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2018;10:133-148. [PMID: 30186577 DOI: 10.15171/mejdd.2018.103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
346 Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6:3303-25. [PMID: 25195642 DOI: 10.3390/nu6083303] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 8.5] [Reference Citation Analysis]
347 Sengupta D, Cassel T, Teng KY, Aljuhani M, Chowdhary VK, Hu P, Zhang X, Fan TW, Ghoshal K. Regulation of hepatic glutamine metabolism by miR-122. Mol Metab 2020;34:174-86. [PMID: 32180557 DOI: 10.1016/j.molmet.2020.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
348 Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2014;. [PMID: 24973316 DOI: 10.1136/gutjnl-2014-306996] [Cited by in Crossref: 288] [Cited by in F6Publishing: 275] [Article Influence: 36.0] [Reference Citation Analysis]
349 Oliveira KG, Malta FM, Nastri AC, Widman A, Faria PL, Santana RA, Alves VA, Carrilho FJ, Pinho JR. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 2016;205:111-7. [PMID: 26272127 DOI: 10.1007/s00430-015-0431-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
350 Toh TB, Lim JJ, Chow EK. Epigenetics of hepatocellular carcinoma. Clin Transl Med. 2019;8:13. [PMID: 31056726 DOI: 10.1186/s40169-019-0230-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
351 Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer 2015;15:542. [PMID: 26206264 DOI: 10.1186/s12885-015-1562-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
352 Cao L, Wan Q, Li F, Tang CE. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep 2018;51:456-61. [PMID: 30037365 [PMID: 30037365 DOI: 10.5483/bmbrep.2018.51.9.104] [Cited by in Crossref: 21] [Article Influence: 5.3] [Reference Citation Analysis]
353 Luna JM, Barajas JM, Teng KY, Sun HL, Moore MJ, Rice CM, Darnell RB, Ghoshal K. Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer. Mol Cell 2017;67:400-410.e7. [PMID: 28735896 DOI: 10.1016/j.molcel.2017.06.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
354 Flamant S, Chomel JC, Desterke C, Féraud O, Gobbo E, Mitjavila-Garcia MT, Foudi A, Griscelli F, Turhan AG, Bennaceur-Griscelli A. Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells. Int J Mol Sci 2019;20:E1737. [PMID: 30965622 DOI: 10.3390/ijms20071737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Sun HL, Cui R, Zhou J, Teng KY, Hsiao YH, Nakanishi K, Fassan M, Luo Z, Shi G, Tili E, Kutay H, Lovat F, Vicentini C, Huang HL, Wang SW, Kim T, Zanesi N, Jeon YJ, Lee TJ, Guh JH, Hung MC, Ghoshal K, Teng CM, Peng Y, Croce CM. ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. Cancer Cell 2016;30:723-36. [PMID: 27846390 DOI: 10.1016/j.ccell.2016.10.001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]